HB3595, titled the Safe Prescribing Through Reporting Act of 2025, would amend the Public Health Service Act to allow certain records about substance use disorder medications to be disclosed to a state’s prescription drug monitoring program (PDMP) when state law requires that disclosure. The bill is narrowly focused on records tied to the prescribing or dispensing of medications used to treat substance use disorders, such as medications for opioid use disorder, and it creates a specific exception to existing confidentiality rules for those records.
In practical terms, the bill would make it easier for states to require reporting of these medication records into PDMP systems, which are used to track controlled substance prescribing and dispensing. The measure is intended to support safer prescribing, improve visibility for clinicians and regulators, and potentially reduce misuse, diversion, or unsafe medication combinations involving substance use disorder treatment drugs.
Impact
The bill would amend section 543(b)(2) of the Public Health Service Act, which governs confidentiality of substance use disorder treatment records, by adding a new disclosure exception for state PDMPs. It would affect providers, pharmacies, treatment programs, and state agencies in states that choose to require such reporting, while leaving the disclosure contingent on applicable state law rather than mandating a nationwide reporting requirement. The change would likely interact with existing privacy protections for substance use disorder records and state prescription monitoring statutes.
Sentiment
Based on the bill text and the absence of recorded committee debate or votes, the available context suggests a generally supportive, public-health-oriented purpose rather than a contested partisan measure. The bill’s title and structure frame it as a patient-safety and reporting bill aimed at improving safe prescribing and oversight. Because there are no transcripts or votes provided, there is no documented opposition or support to characterize beyond the bill’s apparent policy intent.
Contention
The main potential point of contention is the balance between improving prescription monitoring and preserving confidentiality for substance use disorder treatment records. Supporters would likely emphasize safer prescribing, better coordination, and reduced diversion, while critics may worry about privacy, stigma, and the possibility that expanded reporting could discourage patients from seeking treatment. Another possible issue is federal-state interaction, since the bill relies on state law to trigger disclosure and could create uneven reporting requirements across states.